---
title: "摩根大通重申對 Ideaya Biosciences（IDYA）的買入評級"
description: "Rama 關注醫療保健行業，重點分析 Sarepta Therapeutics、IDEAYA Biosciences 和 AnaptysBio 等股票。根據 TipRanks 的數據，Rama 推薦股票的平均回報率為 1.8%，成功率為 46.75%。目前，分析師對 IDEAYA Biosciences 的共識評級為強烈買入，平均目標價為 48.64 美元，比當前水平有 66.23% 的上漲空間。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/261879181.md"
published_at: "2025-10-20T12:05:09.000Z"
---

# 摩根大通重申對 Ideaya Biosciences（IDYA）的買入評級

> Rama 關注醫療保健行業，重點分析 Sarepta Therapeutics、IDEAYA Biosciences 和 AnaptysBio 等股票。根據 TipRanks 的數據，Rama 推薦股票的平均回報率為 1.8%，成功率為 46.75%。目前，分析師對 IDEAYA Biosciences 的共識評級為強烈買入，平均目標價為 48.64 美元，比當前水平有 66.23% 的上漲空間。在昨天發佈的一份報告中，花旗也維持了該股票的買入評級，目標價為 64.00 美元

Rama 關注醫療保健行業，重點關注 Sarepta Therapeutics、IDEAYA Biosciences 和 AnaptysBio 等股票。根據 TipRanks 的數據，Rama 的平均回報率為 1.8%，推薦股票的成功率為 46.75%。

目前，分析師對 IDEAYA Biosciences 的共識評級為強烈買入，平均目標價為 48.64 美元，比當前水平有 66.23% 的上漲空間。在昨天發佈的一份報告中，花旗也維持了該股票的買入評級，目標價為 64.00 美元。

### Related Stocks

- [IDYA.US - Ideaya Biosciences](https://longbridge.com/zh-HK/quote/IDYA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| IDEAYA Biosciences, Inc. $IDYA Stake Lifted by SG Americas Securities LLC | SG Americas Securities LLC increased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 169.1% in Q3, owning 54,137  | [Link](https://longbridge.com/zh-HK/news/272895771.md) |
| Truist Financial Keeps Their Buy Rating on IDEAYA Biosciences (IDYA) | Truist Financial analyst Gregory Renza has maintained a Buy rating on IDEAYA Biosciences (IDYA) with a price target of $ | [Link](https://longbridge.com/zh-HK/news/271649330.md) |
| Evercore ISI Sticks to Their Buy Rating for CVS Health (CVS) | Evercore ISI analyst Elizabeth Anderson maintained a Buy rating on CVS Health (CVS) with a price target of $100.00. Ande | [Link](https://longbridge.com/zh-HK/news/275622408.md) |
| J.P. Morgan Reaffirms Their Buy Rating on Sartorius (0NIR) | J.P. Morgan analyst Richard Vosser has reaffirmed a Buy rating on Sartorius (0NIR) with a price target of €295.00. Vosse | [Link](https://longbridge.com/zh-HK/news/275586209.md) |
| Berenberg Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) | Berenberg Bank analyst Kerry Holford has reaffirmed a Buy rating on Novo Nordisk (0QIU) with a price target of DKK360.00 | [Link](https://longbridge.com/zh-HK/news/275719942.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。